By Bachem AG
To get in touch with Bachem AG, simply fill out the form below.
Subscribe to Supplier
Bachem heralds Industry 4.0 biologics manufacturing at TIDES Asia 2023
Bubendorf, Switzerland: –Leading CDMO, Bachem AG will again be a high profile presence at this year’s TIDES Asia oligonucleotide and peptide therapies symposium in the ancient Japanese city of Kyoto.
Bachem will both be a gold sponsor of the event and a contributor to the agenda, with two presentations on its Industry 4.0 manufacturing vision for peptides and oligomers and risk management it its synthetic peptide CMC Development.
Peptide and oligonucleotide capabilities
The Bachem stand at Booth 23 in the Exhibition Zone at The Westin Miyako Hotel in Kyoto will showcase its comprehensive portfolio of research and production-focused custom synthesis services catering for milligram up to kilogram scales as well as its developing capabilities in therapeutic oligonucleotides.
A strong Bachem team at the event will include its VP for Business Development & Sales Asia Gary Hu, Head of Business Development & Sales Asia Pacific Naoki Yamamoto, VP & Head of Global Business Development Chris McGee, Chief Marketing Officer Torsten Wöhr, and Sales Assistant Keiko Nomura.
The Bachem relationship with TIDES Asia extends back almost a full decade and the Swiss-based company has always been one of the event’s leading sponsors, with the Asian market, and Japan in particular, becoming increasingly important in its core business in therapeutic peptide and oligo development and manufacturing.
Towards Industry 4.0 CMC
Bachem will also give two presentations to the conference, both forming part of the main conference session CMC Strategies for Oligonucleotides and Peptides.
The first, from VP Head Oligonucleotides Dr. Daniel Samson, will cover Bachem’s ‘Implementation Of Industry 4.0 Concepts For Manufacturing Of Oligonucleotides And Peptides’ (Tuesday March 8, 1345- 1415 hrs.). Dr. Samson will show how Bachem’s manufacturing processes for ‘tides drug substances increasingly align with the Industry 4.0 (fourth industrial revolution) concept of full automation and digitalization of manufacturing processes through smart technology and integration, with “smart factory” interconnected and interoperable machines able to process data autonomously and act with very limited human decision making or intervention.
In the second Bachem contribution, Senior Production Director Christopher Martin will present ‘CMC Development of Peptides, a Case Study’ (1615- 1645 hrs.) that will show how an effective CMC strategy for any peptide API needs to include risk mitigation approaches suitable for the intended clinical or commercial phase. His case study will trace development and technology transfer of Lanreotide as an example of a peptide API process tailored to specific regulatory route and application.
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
For further information, see www.bachem.com.
About TIDES Asia 2023
The TIDES Asia Oligonucleotide & Peptide Therapeutics conference is the only event in Asia bringing together science, technologies and partners to accelerate oligonucleotide and peptide molecules to market. The event provides a platform for industry leaders and service providers to share knowledge and insights the oligonucleotide, peptide, mRNA and drug delivery spectrum.
The 2023 meeting is a three-day hybrid event opening March 7 at the Westin Miyako hotel in Kyoto with an accompanying online dimension. The physical conference is expected to attract more than 300 oligonucleotide and peptide experts from across Asia, Europe and North America.
It will feature numerous keynote addresses from leading practitioners in the biologics field as well as workshops on early drug development and CMC of oligonucleotide therapeutics and strategies and techniques to improve the drug-like properties of peptides throughout the product lifecycle.
The co-located exhibition will feature displays from more than 20 global technology leaders, as well as peer-submitted posters that contain new and unpublished research from scientists working across all phases of oligonucleotide and peptide development.
The event is organized by Informa Connect (knect 365) with further information at https://informaconnect.com/asia-tides/